{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:21:39Z","timestamp":1758759699720,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.yapd.2017.03.015","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:15:28Z","timestamp":1499300128000},"page":"13-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunization Update VI"],"prefix":"10.1016","volume":"64","author":[{"given":"Ayesha","family":"Mirza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yapd.2017.03.015_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0036-1592070","article-title":"Vaccine development for Zika Virus- Timelines and Strategies","volume":"34","author":"Durbin","year":"2016","journal-title":"Semin Reprod Med"},{"issue":"4","key":"10.1016\/j.yapd.2017.03.015_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2016-2527","article-title":"Recommendations for prevention and control of influenza in children, 2016-2017","volume":"138","author":"AAP Committee on Infectious Diseases","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.yapd.2017.03.015_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yapd.2013.04.001","article-title":"Immunization update IV","volume":"60","author":"Mirza","year":"2013","journal-title":"Adv Pediatr"},{"key":"10.1016\/j.yapd.2017.03.015_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.yapd.2015.04.004","article-title":"Immunization update V","volume":"62","author":"Mirza","year":"2015","journal-title":"Adv Pediatr"},{"key":"10.1016\/j.yapd.2017.03.015_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.yapd.2017.03.015_bib6","first-page":"1808","article-title":"Factors contributing to the immunogenicity of meningococcal conjugate vaccines","volume":"12","author":"Br\u00f6ker","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.yapd.2017.03.015_bib7","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.yapd.2017.03.015_bib8","unstructured":"MMWR. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr6202a1.htm. Accessed October 10, 2016"},{"key":"10.1016\/j.yapd.2017.03.015_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitides disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yapd.2017.03.015_bib10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1365-3156.2007.01929.x","article-title":"Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci","volume":"12","author":"Dellicour","year":"2007","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.yapd.2017.03.015_bib11","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jadohealth.2016.03.040","article-title":"Prevention of meningococcal infection in the United States: current recommendations and future considerations","volume":"59","author":"Baker","year":"2016","journal-title":"J\u00a0Adolesc Health"},{"key":"10.1016\/j.yapd.2017.03.015_bib12","doi-asserted-by":"crossref","first-page":"e20161890","DOI":"10.1542\/peds.2016-1890","article-title":"Recommendations for Serogroup B Meningococcal vaccine for persons 10 years and older","volume":"138","author":"AAP Committee on Infectious Diseases","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.yapd.2017.03.015_bib13","unstructured":"CDC-ACIP. Available at: https:\/\/www.cdc.gov\/vaccines\/acip\/index.html. Accessed October 26, 2016."},{"issue":"43","key":"10.1016\/j.yapd.2017.03.015_bib14","first-page":"1189","article-title":"Recommendations for use of meningococcal conjugate vaccines in HIV-infections persons \u2013Advisory Committee on Immunizations Practices, 2016","volume":"65","author":"CDC","year":"2016","journal-title":"MMWR Weekly"},{"key":"10.1016\/j.yapd.2017.03.015_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population level impact and herd effects following human papillomavirus vaccination programs: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.yapd.2017.03.015_bib16","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/cid\/ciw533","article-title":"Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community","volume":"63","author":"Kahn","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yapd.2017.03.015_bib17","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1542\/peds.2011-3587","article-title":"Vaccine type human papillomavirus and evidence of herd protection after vaccine introduction","volume":"130","author":"Kahn","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.yapd.2017.03.015_bib18","first-page":"e1","article-title":"Population based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era","author":"Benard","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.yapd.2017.03.015_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6533a4","article-title":"National, regional, state and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2015","volume":"65","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.yapd.2017.03.015_bib20","unstructured":"Healthy People 2020. Available at: https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization-and-infectious-diseases\/objectives. Accessed November 12, 2016."},{"key":"10.1016\/j.yapd.2017.03.015_bib21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2105\/AJPH.2016.303286","article-title":"Human papillomavirus vaccination requirements in US schools: recommendations for moving forward","volume":"106","author":"North","year":"2016","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.yapd.2017.03.015_bib22","first-page":"300","article-title":"Use of 9-valent Human Papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"CDC","year":"2015","journal-title":"MMWR"},{"issue":"43","key":"10.1016\/j.yapd.2017.03.015_bib23","first-page":"465","article-title":"Human papillomavirus vaccines: WHO position paper, October 2014","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"issue":"4","key":"10.1016\/j.yapd.2017.03.015_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/infdis\/jiw036","article-title":"Randomized open trial comparing 2-dose regimens of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in girls aged 9-14 years vs a 3-dose regimen in women aged 15-25 years","volume":"214","author":"Puthanakit","year":"2016","journal-title":"J\u00a0Infect Dis"},{"issue":"12","key":"10.1016\/j.yapd.2017.03.015_bib25","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum Vacc"},{"issue":"22","key":"10.1016\/j.yapd.2017.03.015_bib26","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.2016.16393","article-title":"Two vs three doses of human papillomavirus vaccine new policy for the second decade of the vaccination program","volume":"316","author":"Markowitz","year":"2016","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.yapd.2017.03.015_bib27","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2016.17615","article-title":"Immunogenicity of the 9-Valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women","volume":"316","author":"Iversen","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.yapd.2017.03.015_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/21645515.2015.1058458","article-title":"Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes","volume":"12","author":"Hern\u00e1ndez-\u00c1vila","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"10.1016\/j.yapd.2017.03.015_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.yapd.2017.03.015_bib30","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1016\/j.vaccine.2016.09.042","article-title":"Manufacturing costs of HPV vaccines for developing countries","volume":"34","author":"Clendinen","year":"2016","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"10.1016\/j.yapd.2017.03.015_bib31","first-page":"D1","article-title":"Human papillomavirus (HPV) and related cancers in the global alliance for vaccines and immunization (GAVI) countries. A WHO\/ICO HPV Information Centre Report","volume":"30","author":"de Sanjos\u00e9","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.yapd.2017.03.015_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamapediatrics.2015.4875","article-title":"Impact of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: a follow up analysis","volume":"170","author":"Skoff","year":"2016","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.yapd.2017.03.015_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMc1212006","article-title":"Priming with whole-cell versus acellular pertussis vaccine","volume":"368","author":"Liko","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.yapd.2017.03.015_bib34","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.yapd.2017.03.015_bib35","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.vaccine.2016.03.049","article-title":"Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015","volume":"34","author":"Moro","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.yapd.2017.03.015_bib36","first-page":"1","article-title":"Effectiveness of prenatal versus postpartum tetanus, diphtheria and acellular tetanus vaccination in preventing infant pertussis","author":"Winter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.yapd.2017.03.015_bib37","unstructured":"GAVI. Available at: http:\/\/www.gavi.org\/. Accessed November 12, 2016."},{"key":"10.1016\/j.yapd.2017.03.015_bib38","unstructured":"CDC. Ebola (Ebola Virus Disease). Available at: http:\/\/www.cdc.gov\/vhf\/ebola\/strive\/qa.html. Accessed November 13, 2016."},{"key":"10.1016\/j.yapd.2017.03.015_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14760584.2016.1178069","article-title":"New insights into the global burden of noroviruses and opportunities for prevention","volume":"15","author":"Hall","year":"2016","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.yapd.2017.03.015_bib40","doi-asserted-by":"crossref","first-page":"e0151219","DOI":"10.1371\/journal.pone.0151219","article-title":"Global economic burden of norovirus gastroenteritis","volume":"11","author":"Bartsch","year":"2016","journal-title":"PLoS One"},{"issue":"Suppl 5","key":"10.1016\/j.yapd.2017.03.015_bib41","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1016\/j.cmi.2015.12.023","article-title":"Vaccines against norovirus: state of the art trials in children and adults","volume":"22","author":"Baehner","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.yapd.2017.03.015_bib42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized control trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.yapd.2017.03.015_bib43","unstructured":"CDC. Measles. Available at: http:\/\/www.cdc.gov\/measles\/cases-outbreaks.html. Accessed November 13, 2016."},{"key":"10.1016\/j.yapd.2017.03.015_bib44","unstructured":"California Legislative Information. SB-277 Public health: vaccinations. Available at: https:\/\/leginfo.legislature.ca.gov\/faces\/billNavClient.xhtml?bill_id=201520160SB277 Accessed November 13, 2016"},{"key":"10.1016\/j.yapd.2017.03.015_bib45","doi-asserted-by":"crossref","first-page":"e20162145","DOI":"10.1542\/peds.2016-2145","article-title":"Medical versus nonmedical immunization exemptions for child care and school entry","volume":"138","year":"2016","journal-title":"Pediatrics"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310117300154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310117300154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:10:20Z","timestamp":1758744620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310117300154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0065310117300154"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2017.03.015","relation":{},"ISSN":["0065-3101"],"issn-type":[{"type":"print","value":"0065-3101"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization Update VI","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2017.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}